Concepedia

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Francesco Massari, Veronica Mollica, Ondřej Fiala, Ugo De Giorgi, Jakub Kucharz, Maria Giuseppa Vitale, Javier Molina‐Cerrillo, Gaetano Facchini, Emmanuel Seront, Edoardo Lenci,

European Urology Oncology · 2024 · 13 citations · 19 references

DOIFull text

Open access

Concepts

References

19

RECIST 1.1—Update and clarification: From the RECIST committee

Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries et al. · European Journal of Cancer · 2016 · 1.9K citations

, , +3

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

New England Journal of Medicine · 2015 · 1.4K citations · Full text

, , +17

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir, Eric Jonasch, Laurence Albigès et al. · European Urology · 2015 · 360 citations · Full text

, , +14

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology · 2021 · 287 citations · Full text

, , +17

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal, Catherine M. Tangen, Ian M. Thompson et al. · The Lancet · 2021 · 279 citations · Full text

, , +11